Prevalence and number of circulating tumour cells and microemboli at diagnosis of advanced NSCLC

Mascalchi, Mario; Falchini, Massimo; Maddau, Cristina; Salvianti, Francesca; Nistri, M; Bertelli, Elena; Sali, Lapo; Zuccherelli, Stefania; Vella, Alessandra; Matucci, Marzia; Voltolini, Luca; Pegna, Andrea Lopes; Luconi, Michaela; Pinzani, Pamela; Pazzagli, Mario

doi:10.1007/s00432-015-2021-3

Cited by 47 publications

(43 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This could partly be explained by the subjective nature of the method of identification, particularly in the absence of any special or specific antibody stains. However, our detection rates were similar in comparison to studies looking at patients with more advanced NSCLC with 60% for both Pathologists, although it must be noted the advanced cancer sample numbers comprised a very small proportion of the cohort, Mascalchi et al (2015) reported detection rates of CTCs using ScreenCell of 65% in a cohort of 26 patients with stage III and IV NSCLC. The authors found no correlation between tumour stage and the number of CTCs detected (27).…”

Section: Discussionsupporting

confidence: 78%

“…However, our detection rates were similar in comparison to studies looking at patients with more advanced NSCLC with 60% for both Pathologists, although it must be noted the advanced cancer sample numbers comprised a very small proportion of the cohort, Mascalchi et al (2015) reported detection rates of CTCs using ScreenCell of 65% in a cohort of 26 patients with stage III and IV NSCLC. The authors found no correlation between tumour stage and the number of CTCs detected (27). Our detection rates, in comparison to other studies, support the idea that the release of CTCs is not related to tumour stage.…”

Section: Discussionsupporting

confidence: 78%

See 1 more Smart Citation

Detection of Circulating Tumour Cells and Survival of Patients with Non-Small Cell Lung Cancer

Chudasama

Barr

Beeson

et al. 2017

View full text Add to dashboard Cite

Section: Discussionsupporting

confidence: 78%

Section: Discussionsupporting

confidence: 78%

Detection of Circulating Tumour Cells and Survival of Patients with Non-Small Cell Lung Cancer

Chudasama

Barr

Beeson

et al. 2017

View full text Add to dashboard Cite

“…We did not find any correlation or association of CTCs/CTM with white blood cells (leukocyte, neutrophil, or lymphocyte). Additionally, there was no significant correlation between CTC number and CTM number in our study as in a previous study of non-small cell lung cancer (23 ). The disparity in the range of CTC numbers of PDAC and other cancers might have originated from tumor characteristics and the platforms used.…”

Section: Discussioncontrasting

confidence: 59%

Clinical Significance of Circulating Tumor Microemboli as a Prognostic Marker in Patients with Pancreatic Ductal Adenocarcinoma

Chang

Chen

et al. 2016

Clinical Chemistry

View full text Add to dashboard Cite

BACKGROUND Characterization of circulating tumor cells (CTCs) has been used to provide prognostic, predictive, and pharmacodynamic information in many different cancers. However, the clinical significance of CTCs and circulating tumor microemboli (CTM) in patients with pancreatic ductal adenocarcinoma (PDAC) has yet to be determined. METHODS In this prospective study, CTCs and CTM were enumerated in the peripheral blood of 63 patients with PDAC before treatment using anti-EpCAM (epithelial cell adhesion molecule)–conjugated supported lipid bilayer–coated microfluidic chips. Associations of CTCs and CTM with patients' clinical factors and prognosis were determined. RESULTS CTCs were abundant [mean (SD), 70.2 (107.6)] and present in 81% (51 of 63) of patients with PDAC. CTM were present in 81% (51 of 63) of patients with mean (SD) 29.7 (1101.4). CTM was an independent prognostic factor of overall survival (OS) and progression free survival (PFS). Patients were stratified into unfavorable and favorable CTM groups on the basis of CTM more or less than 30 per 2 mL blood, respectively. Patients with baseline unfavorable CTM, compared with patients with favorable CTM, had shorter PFS (2.7 vs 12.1 months; P < 0.0001) and OS (6.4 vs 19.8 months; P < 0.0001). Differences persisted if we stratified patients into early and advanced diseases. The number of CTM before treatment was an independent predictor of PFS and OS after adjustment for clinically significant factors. CONCLUSIONS The number of CTM, instead of CTCs, before treatment is an independent predictor of PFS and OS in patients with PDAC.

show abstract

“…ScreenCell ® technology is a range of specific devices and has been validated for the detection and molecular analysis of CTCs in several other solid tumors including prostate, pancreatic cancer, renal, colon, and lung [16,17,18,19,20,21]. Without surface-marker selection, size-execution method allows the capture of all types of circulating tumor associated cells in one blood draw and exploring the phenotypic and genetic heterogeneity of these cells.…”

Section: Introductionmentioning

confidence: 99%

Detection and Characterization of Circulating Tumor Associated Cells in Metastatic Breast Cancer

Benali-Furet²,

Uzan³

et al. 2016

IJMS

View full text Add to dashboard Cite

The availability of blood-based diagnostic testing using a non-invasive technique holds promise for real-time monitoring of disease progression and treatment selection. Circulating tumor cells (CTCs) have been used as a prognostic biomarker for the metastatic breast cancer (MBC). The molecular characterization of CTCs is fundamental to the phenotypic identification of malignant cells and description of the relevant genetic alterations that may change according to disease progression and therapy resistance. However, the molecular characterization of CTCs remains a challenge because of the rarity and heterogeneity of CTCs and technological difficulties in the enrichment, isolation and molecular characterization of CTCs. In this pilot study, we evaluated circulating tumor associated cells in one blood draw by size exclusion technology and cytological analysis. Among 30 prospectively enrolled MBC patients, CTCs, circulating tumor cell clusters (CTC clusters), CTCs of epithelial–mesenchymal transition (EMT) and cancer associated macrophage-like cells (CAMLs) were detected and analyzed. For molecular characterization of CTCs, size-exclusion method for CTC enrichment was tested in combination with DEPArray™ technology, which allows the recovery of single CTCs or pools of CTCs as a pure CTC sample for mutation analysis. Genomic mutations of TP53 and ESR1 were analyzed by targeted sequencing on isolated 7 CTCs from a patient with MBC. The results of genomic analysis showed heterozygous TP53 R248W mutation from one single CTC and pools of three CTCs, and homozygous TP53 R248W mutation from one single CTC and pools of two CTCs. Wild-type ESR1 was detected in the same isolated CTCs. The results of this study reveal that size-exclusion method can be used to enrich and identify circulating tumor associated cells, and enriched CTCs were characterized for genetic alterations in MBC patients, respectively.

show abstract

Prevalence and number of circulating tumour cells and microemboli at diagnosis of advanced NSCLC

Abstract: CTC can be detected in two-thirds and CTM in more than half of patients with advanced NSCLC at diagnosis. Reasons underlying lack of CTC and CTM in some advanced lung cancers deserve further investigations.

Cited by 47 publications

References 20 publications

Detection of Circulating Tumour Cells and Survival of Patients with Non-Small Cell Lung Cancer

Detection of Circulating Tumour Cells and Survival of Patients with Non-Small Cell Lung Cancer

Clinical Significance of Circulating Tumor Microemboli as a Prognostic Marker in Patients with Pancreatic Ductal Adenocarcinoma

Detection and Characterization of Circulating Tumor Associated Cells in Metastatic Breast Cancer

Contact Info

Product

Resources

About